3-{1-azatricyclo[6.3.1.0',¹²]dodeca-2,4,6,8(12)-tetraen-3-yl}-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
CAS: 1239986-50-5
Rif. 3D-PZB98650
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione | ||
250mg | Fuori produzione | ||
500mg | Fuori produzione |
Informazioni sul prodotto
Tivantinib is a monoclonal antibody that targets the MET receptor tyrosine kinase and inhibits its activity. MET is involved in cell proliferation, migration, and adhesion. Tivantinib has been shown to inhibit the growth of metastatic colorectal cancer cells in mice with body masses below 40 g. Tivantinib also has anti-angiogenic properties that may be due to its inhibition of epidermal growth factor (EGF). Tivantinib binds to actin filaments and inhibits the formation of c-met, leading to an increase in the concentration-time curve for tivantinib.